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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and safety of monoclonal antibody therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) compared with
placebo in the treatment of adults with COPD.
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a common
condition characterised by persistent respiratory symptoms and
airflow limitation. Chronic exposure to noxious particles or gases,
most commonly tobacco smoke, leads to inflammation and nar-
rowing of the airways (bronchitis) and parenchymal destruction
(emphysema) (GOLD 2019). The cardinal symptoms are breath-
lessness, reduced exercise tolerance, wheeze and cough. COPD
differs from asthma, the other major chronic airway disease, be-
cause its symptoms and airflow obstruction are not fully reversible.
Acute exacerbations of COPD, which involve increased airway in-
flammation and sputum production, lead to increased symptoms
beyond usual day-to-day variability. They are a major cause of
morbidity, mortality, hospital admissions, and reduced quality of
life for people living with COPD.
The global prevalence of COPD was estimated to be 251 million
cases in 2016, accounting for 3.17 million deaths (5% of all deaths
globally) during the previous year. It is projected to become the
third leading cause of death worldwide by 2030 (WHO 2019a;
WHO 2019b). In the UK, 4.5% of the population aged over 40
have a diagnosis of COPD (BLF 2019).
Phenotypic variation is seen between COPD patients, with vari-
ation in the proportion of cell types and cytokine profiles in af-
fected airways. In more advanced disease, neutrophils and B lym-
phocytes predominate (Hogg 2004). A proportion of cases have
eosinophilic airway inflammation, with elevated eosinophil counts
in sputum or blood samples (blood eosinophilia > 2% was found
in 37% of one cohort) (Singh 2014). Phenotypic clusters have also
been identified during acute exacerbations, with up to 40% show-
ing an eosinophil-predominant Th2 inflammatory profile (Saha
2006).
This has led to investigation into whether biomarkers, such as
eosinophil levels, are associated with disease severity, exacerbation
rates, and response to specific treatments. Correlation has been
observed between elevated blood eosinophil levels and higher se-
vere COPD exacerbation rates (Couillard 2017). The addition
of an inhaled corticosteroid (ICS) to long-acting beta -agonist
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(LABA) therapy was more effective in preventing exacerbations in
those with eosinophilia (Pascoe 2015). Systemic steroid treatment
appears to be more effective in exacerbations where there is spu-
tum or blood eosinophilia (Bafadhel 2012; Bafadhel 2014). These
data point towards eosinophils playing a role in the pathogenesis of
COPD, particularly during exacerbations, in a subset of patients.
Description of the intervention
Corticosteroids suppress inflammation non-specifically and are ef-
fective in many patients with asthma or COPD; a notable propor-
tion, however, are poorly responsive. Moreover, frequent or con-
tinuous systemic corticosteroid use carries the risk of added mor-
bidity, such as adrenal suppression, hyperglycaemia, osteoporosis
and skin thinning.
In the search for more targeted treatments, monoclonal antibody
(MAb) technology has been employed, with anti-IL-5 a commonly
used MAb. The appeal of this approach is that MAbs can offer high
affinity and specificity for targets not amenable to small-molecule
drugs. They have revolutionised the management of other con-
ditions, particularly certain connective tissue diseases, inflamma-
tory bowel disease and cancers (Adegbola 2018; Bittner 2018).
In all cases biomarkers are needed which can predict therapeutic
responses, for example eosinophils, which infiltrate the airways.
MAbs can then be directed against immune pathways which may
contribute to the presence of eosinophils, such as interleukin 5
(IL-5).
T helper type 2 (Th2) cells and eosinophils are implicated in both
COPD and asthma. Mediators including interleukin 3 (IL-3), IL-
5 and IL-13 are prominent in Th2-type inflammation, where they
promote eosinophil maturation. IL-5 is particularly key for the
differentiation, proliferation and activation of eosinophils. Th2
cells can also drive airway inflammation via an IgE and mast cell
mechanism. Several biologic drugs targeting Th2-type inflamma-
tion have demonstrated efficacy as an adjunct to corticosteroids in
the management of severe eosinophilic or atopic asthma, with ac-
ceptable side-effect profiles (Farne 2017; Normansell 2014). Con-
sequently, a number of them have been approved for use in this
context, namely omalizumab (anti-IgE), mepolizumab (anti-IL-
5), reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor).
There may also be useful drug targets outside the Th2-eosinophil
pathway, although to date these have not shown such efficacy in
airway diseases (Durham 2016; Nixon 2017).
How the intervention might work
Eosinophilic inflammation has been implicated in a proportion
of patients with COPD, most prominently during exacerbations
(Singh 2014; Siva 2007; Vedel-Krogh 2016). This process has been
effectively targeted in severe eosinophilic asthma. Therefore it is
postulated that MAbs directed against similar targets in COPD
patients with eosinophilic phenotypes may provide therapeutic
benefit.
Why it is important to do this review
Whilst COPD is an irreversible disease, its management is directed
at slowing or halting the decline in lung function, preventing and
aborting exacerbations, and optimising quality of life. Monoclonal
antibody therapies have proven a useful tool for asthma. A recent
Cochrane Review supports the use of anti-IL-5 treatments as an
adjunct to standard treatment in people with severe eosinophilic
asthma, with treatments roughly halving asthma exacerbations
(Farne 2017). Given the number of pathological similarities be-
tween asthma and COPD, it may be that they can benefit at least
a subset of COPD patients too. Anti-IL-5 treatments have not
been approved for use in COPD and they are not mentioned in
guidelines, but as there is an emerging literature in this field it
is important to establish whether they have a role to play or not
(Tan 2018). COPD is such a common condition that any addi-
tional treatments have the potential to benefit a large number of
patients. Exacerbations are a major determinant of both quality
of life and healthcare usage. These drugs reduce exacerbations of
asthma (Farne 2017). If they also reduced exacerbations of COPD
in those with eosinophils that would be good for patients and
healthcare systems.
O B J E C T I V E S
To assess the efficacy and safety of monoclonal antibody thera-
pies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) compared
with placebo in the treatment of adults with COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported in full text, those published as an abstract
only and unpublished data.
Types of participants
We will include adults (≥ 40 years old) with a diagnosis of COPD
as defined by GOLD 2019. We will record study authors’ defini-
tions of the severity of COPD. We will not exclude participants
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with co-morbidities. We will, however, exclude participants with a
substantial asthma component to their disease, either with a label
of “asthma COPD overlap syndrome” (Pavord 2015), or excessive
variation in lung function, defined by a variation of more than
12% and 200 mL in FEV , either between tests or with a bron-
chodilator (GINA 2019).
Types of interventions
We will include studies comparing anti-IL-5 therapy with placebo.
Specifically we will consider anti-IL-5 therapies developed for use
in other airway diseases such as those directed against various
IL-5 targets. We will include studies that allowed participants to
continue using their inhaled therapies including inhaled corticos-
teroids (ICS), long-acting beta -agonist (LABA), and long-acting
muscarinic antagonist (LAMA) or combination inhalers, as long
as these co-interventions are not part of the randomised treatment.
Types of outcome measures
Primary outcomes
1. All exacerbations
2. Hospitalisations due to COPD exacerbation
3. Serious adverse events
4. Quality of life (as measured on a validated scale, e.g. St
George’s Respiratory Questionnaire (SGRQ) or Chronic
Respiratory Disease Questionnaire (CRDQ))
Secondary outcomes
1. Measures of pulmonary function such as FEV , and FVC
2. Exercise performance six-minute walk test and other
measures
3. Self-rated symptom score/symptoms of breathlessness such
as:
i) inhaled rescue medication used during the treatment
period and concomitant medication usage, including antibiotics
and steroids;
ii) number of days (or nights) participant experienced
symptoms;
iii) COPD Assessment Test (CAT) Score; or
iv) COPD Control Questionnare (CCQ) Score.
4. Adverse events/side effects
5. Mortality
Reporting one or more of the outcomes listed here in the study is
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify studies from searches of the following databases
and trial registries.
1. Cochrane Airways Trials Register (Cochrane Airways
2019), via the Cochrane Register of Studies, all years to date
2. Cochrane Central Register of Controlled Trials
(CENTRAL), via the Cochrane Register of Studies, all years to
date
3. MEDLINE Ovid SP 1946 to date
4. Embase Ovid SP 1974 to date
5. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.ClinicalTrials.gov)
6. World Health Organization International Clinical Trials
Registry Platform ( apps.who.int/trialsearch)
The proposed search strategy for the Cochrane Airways Trials Reg-
ister is listed in Appendix 1. This will be adapted for use in the other
databases. The search strategy was developed by the Cochrane Air-
ways Information Specialist in collaboration with the authors.
We will search all databases and trials registries from their inception
to the present, and there will be no restriction on language or
type of publication. Hand-searched conference abstracts and grey
literature will be identified through the Cochrane Airways Trials
Register and the CENTRAL database in the Cochrane Library.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references. We will search relevant manufac-
turers’ web sites for study information.
We will search on PubMed for errata or retractions from included
studies published in full text, and report the date this was done
within the review.
Data collection and analysis
Selection of studies
Two review authors (RW and TD) will screen the titles and ab-
stracts of the search results independently and code them as ’re-
trieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’.
We will retrieve the full-text study reports of all potentially eligible
studies and two review authors (IC and PB) will independently
screen them for inclusion, recording the reasons for exclusion of
ineligible studies. We will resolve any disagreement through dis-
cussion or, if required, we will consult a third person/review au-
thor (RW, TD or SM). We will identify and exclude duplicates
and collate multiple reports of the same study so that each study,
rather than each report, is the unit of interest in the review. We
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will record the selection process in sufficient detail to complete a
PRISMA flow diagram and ’Characteristics of excluded studies’
table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in
the review. Two review authors (RW and TD) will extract the
following study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Two review authors (IC and PB) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus or
by involving a third person/review author (RW, TD or SM). One
review author (TD) will transfer data into the Review Manager 5
file (Review Manager 2014). We will double-check that data are
entered correctly by comparing the data presented in the system-
atic review with the study reports. A second review author (RW)
will spot-check study characteristics for accuracy against the study
report.
Assessment of risk of bias in included studies
Two review authors (RW and TD) will assess risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (IC, PB or SM). We will assess the risk of bias
according to the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We will judge each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgement in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR) and con-
tinuous data as the mean difference (MD) or standardised mean
difference (SMD). If we combine data from rating scales in a meta-
analysis, we will ensure they are entered with a consistent direction
of effect (e.g. lower scores always indicate improvement).
We will undertake meta-analyses only where this is meaningful;
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense.
We will describe skewed data narratively (for example, as medians
and interquartile ranges for each group).
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If we combine two comparisons
(e.g. drug A versus placebo and drug B versus placebo) in the same
meta-analysis, we will either combine the active arms or halve the
control group to avoid double-counting.
If adjusted analyses are available (ANOVA or ANCOVA) we will
use these as a preference in our meta-analyses. If both change-from-
baseline scores and endpoint scores are available for continuous
data, we will use change-from-baseline scores. If a study reports
outcomes at multiple time points, we will preferentially use 12-
month data but report other time points where appropriate.
We will use intention-to-treat (ITT) or ’full analysis set’ analyses
where they are reported (i.e. those where data have been imputed
for participants who were randomly assigned but did not complete
the study) instead of completer or per protocol analyses.
Unit of analysis issues
For dichotomous outcomes we will use participants, rather than
events, as the unit of analysis (i.e. number of people admitted
to hospital, rather than number of admissions per person). If,
however, rate ratios are reported in a study, we will analyse them
on this basis. We will only meta-analyse data from cluster-RCTs
if the available data have been adjusted (or can be adjusted), to
account for the clustering.
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Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as an abstract
only). Where this is not possible and we think the missing data
introduce serious bias, we will take this into consideration in the
GRADE rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity
we will report it and explore the possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small-study and publi-
cation biases.
Data synthesis
We will use a random-effects model, reported with 95% confi-
dence intervals (CI) and perform a sensitivity analysis with a fixed-
effect model. We will synthesise and report dichotomous and con-
tinuous data separately for each outcome, e.g. hospitalisation/no
hospitalisation or duration of hospitalisation. We will also analyse
odds ratios and report them separately. For a given outcome mea-
sure, we will combine effect estimates, such as differences at end-
point and change from baseline. When outcomes are measured
using different scales, e.g. health-related quality of life, we will use
standardised mean differences (SMD) in the analyses. We will use
the baseline standard deviation (SD) for the SMD analyses.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes: all exacerbations, hospitalisations due to COPD, seri-
ous adverse events, lung function (FEV ) and quality of life. We
will use the five GRADE considerations (risk of bias, consistency
of effect, imprecision, indirectness and publication bias) to assess
the quality of a body of evidence as it relates to the studies that con-
tribute data for the prespecified outcomes. We will use the meth-
ods and recommendations described in Section 8.5 and Chapter
12 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), using GRADEpro software (GRADEpro GDT).
We will justify all decisions to downgrade the quality of studies
using footnotes and we will make comments to aid the reader’s
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Baseline serum eosinophil counts (> 0.3 vs ≤ 0.3 × 10
per litre of blood)
2. Baseline COPD severity using GOLD 2019 classification
We will use our primary outcomes in the subgroup analyses.
We will use the formal test for subgroup interactions in Review
Manager 5 (Review Manager 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses, removing
the following from the primary outcome analyses.
1. A comparison of available case analysis to true ITT
analyses, where the ITT analyses are imputed.
2. A comparison based on the risk of bias assessment where
trials are judged to be at high risk of bias for any of the six
domains.
We will compare the results from a fixed-effect model with the
random-effects model.
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A P P E N D I C E S
Appendix 1. Database search strategy
Database: Cochrane Airways Register of Trials
Platform: Cochrane Register of Studies
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR AECOPD OR AECB):TI,AB,KW
#6 #1 OR #2 OR #3 OR #5 OR #4
#7 MESH DESCRIPTOR Antibodies, Monoclonal
#8 MESH DESCRIPTOR Antibodies, Monoclonal, Humanized
#9 mepolizumab
#10 SB24056 or SB-24056
#11 Bosatria or Nucala
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#20 MESH DESCRIPTOR Interleukin-5 EXPLODE ALL
#21 MESH DESCRIPTOR Receptors, Interleukin-5 EXPLODE ALL
#22 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #22 AND #6
C O N T R I B U T I O N S O F A U T H O R S
TD: contributed to Methods, Data collection and Analysis sections
SM: contributed to Background and Methods sections
RW: contributed to Methods, Data collection and Analysis sections
IC: contributed to Methods section
PB: contributed to Background and Methods sections
Contributions of editorial team
Rebecca Fortescue (Coordinating Editor): edited the protocol; advised on methodology; approved the protocol prior to publication.
Chris Cates (Coordinating Editor) checked the planned methods.
Han Ni (Contact Editor): edited the protocol and advised on content.
Emma Dennett (Managing Editor): coordinated the editorial process; advised on content; edited the protocol.
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